Interactions between poly(ethylene glycol) and protein in dichloromethane/water emulsions: A study of interfacial properties

From adsorption kinetics and interfacial rheological studies performed by using a pendant-drop method, i.e. in conditions close to those of the primary emulsion of the water-in-oil-in-water emulsion-encapsulation technique, it was shown that adsorption of the hen egg-white lysozyme (HEWL) at the water/dichloromethane (DCM) interface can be efficiently slowed down by modulating some parameters. It was shown that a decrease of the ionic strength of the aqueous phase, and the optimization of the density of the poly(ethylene glycol) (PEG) adsorbed film by increasing the PEG concentration or by modulating the polymer chain length, can significantly decrease the rate of adsorption of HEWL at the water/DCM interface. Moreover, it was shown that the choice of the dissolution phase of PEG (DCM or water) clearly influences the results

Interactions between poly(ethylene glycol) and protein in dichloromethane/water emulsions. 2. Conditions required to obtain spontaneous emulsification allowing the formation of bioresorbable poly(D,L lactic acid) microparticles

From microscopic observations, it was established that an oil-in-water emulsion with droplets of a size in the micrometer range can spontaneously form at room temperature without additional external stirring as soon as a solvent that is only partly miscible to water-like dichloromethane (DCM) is put in contact with an aqueous mixture of polyethylene glycol (PEG) and a protein. Experimental results show that emulsification only occurs if the system simultaneously includes PEG with middle chain, an organic solvent partly miscible to water and for which PEG affinity is sufficiently high, and a protein. From adsorption kinetics, it appears that this spontaneous emulsification process is related to the rapid diffusion of DCM towards water through the formation of interfacial turbulences, once the accumulation of PEG close to the DCM/water interface occurs. The oil droplets formed would be then stabilized by adsorbed protein molecules. Since the presence of polylactic acid in the organic phase did not prevent the emulsion formation, we studied the feasibility of formulating microparticles using this polymer. From results, it appears that microcapsules with a polymeric shell, with a homogeneous size of about 50 microm and able to encapsulate a model hydrophobic drug, such as amiodarone, can be obtained by using this spontaneous emulsification method

Antikinetoplastid SAR study in 3-nitroimidazopyridine series: identification of a novel non-genotoxic and potent anti-T. b. brucei hit-compound with improved pharmacokinetic properties

To study the antikinetoplastid 3-nitroimidazo[1,2-a]pyridine pharmacophore, a structure-activity relationship study was conducted through the synthesis of 26 original derivatives and their in vitro evaluation on both Leishmania spp and Trypanosoma brucei brucei. This SAR study showed that the antitrypanosomal pharmacophore was less restrictive than the antileishmanial one and highlighted positions 2, 6 and 8 of the imidazopyridine ring as key modulation points. None of the synthesized compounds allowed improvement in antileishmanial activity, compared to previous hit molecules in the series. Nevertheless, compound 8, the best antitrypanosomal molecule in this series (EC50 = 17 nM, SI = 2650 & E° = -0.6 V), was not only more active than all reference drugs and previous hit molecules in the series but also displayed improved aqueous solubility and better in vitro pharmacokinetic characteristics: good microsomal stability (T1/2 > 40 min), moderate albumin binding (77%) and moderate permeability across the blood brain barrier according to a PAMPA assay. Moreover, both micronucleus and comet assays showed that nitroaromatic molecule 8 was not genotoxic in vitro. It was evidenced that bioactivation of molecule 8 was operated by T. b. brucei type 1 nitroreductase, in the same manner as fexinidazole. Finally, a mouse pharmacokinetic study showed that 8 displayed good systemic exposure after both single and repeated oral administrations at 100 mg/kg (NOAEL) and satisfying plasmatic half-life (T1/2 = 7.7 h). Thus, molecule 8 appears as a good candidate for initiating a hit to lead drug discovery program

A winning strategy to improve the anticancer properties of Cisplatin and Quercetin based on the nanoemulsions formulation

The aim of the present study was the proposal of a strategy to permit the safe use of the powerful antitumor agent Cisplatin. Considering the possibility of reducing the oxidative stress responsible for the Cisplatin induced nephrotoxicity by using antioxidants, such as flavonoids, we proposed the concomitant therapeutic association of Cisplatin with Quercetin. Considering the poor solubility of Quercetin, nanoemulsions have been proposed to encapsulate and facilitate the use of the drug. Originally, the concomitant encapsulation of Quercetin with Cisplatin has been also assessed. The obtained formulations have been characterized and tested against two human cell models, namely the human breast cancer MDA-MB-231 and the normal HEK-293 renal cells. We demonstrated that the new formulated nanoemulsions have improved the anticancer properties of both the molecules and, most importantly, the synergistic effect of the Cisplatin/Quercetin against the MDA-MB-231. Moreover, the dramatic cytotoxic effects of Cisplatin against the human renal HEK-293 cells have been significantly diminished by the use of nanoemulsions containing both the molecules, whereas the antioxidant properties of encapsulated Quercetin have been improved. Finally, the simple process used to obtain the nanoemulsions and the physico-chemical properties compatible with parenteral administration, the stability and the improved pharmaceutical effects contribute to the high potential of this strategy to be studied in future in vivo studies

Development of a nasal drug delivery composite nanosystem for Alzheimer’s desease treatment

International audienc

Antikinetoplastid SAR study in 3-nitroimidazopyridine series: identification of a novel non-genotoxic and potent anti-T. b. brucei hit-compound with improved pharmacokinetic properties

To study the antikinetoplastid 3-nitroimidazo[1,2-a]pyridine pharmacophore, a structure-activity relationship study was conducted through the synthesis of 26 original derivatives and their in vitro evaluation on both Leishmania spp and Trypanosoma brucei brucei. This SAR study showed that the antitrypanosomal pharmacophore was less restrictive than the antileishmanial one and highlighted positions 2, 6 and 8 of the imidazopyridine ring as key modulation points. None of the synthesized compounds allowed improvement in antileishmanial activity, compared to previous hit molecules in the series. Nevertheless, compound 8, the best antitrypanosomal molecule in this series (EC50 = 17 nM, SI = 2650 & E° = -0.6 V), was not only more active than all reference drugs and previous hit molecules in the series but also displayed improved aqueous solubility and better in vitro pharmacokinetic characteristics: good microsomal stability (T1/2 > 40 min), moderate albumin binding (77%) and moderate permeability across the blood brain barrier according to a PAMPA assay. Moreover, both micronucleus and comet assays showed that nitroaromatic molecule 8 was not genotoxic in vitro. It was evidenced that bioactivation of molecule 8 was operated by T. b. brucei type 1 nitroreductase, in the same manner as fexinidazole. Finally, a mouse pharmacokinetic study showed that 8 displayed good systemic exposure after both single and repeated oral administrations at 100 mg/kg (NOAEL) and satisfying plasmatic half-life (T1/2 = 7.7 h). Thus, molecule 8 appears as a good candidate for initiating a hit to lead drug discovery program